Do analysts prefer CUE or ATNM?

Actinium Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 405.05%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is ATNM or PEPG more profitable?

PepGen's return on equity of -59.89% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% PepGen N/A -59.89% -49.62%

Does the media favor ATNM or PEPG?

In the previous week, PepGen had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for PepGen and 1 mentions for Actinium Pharmaceuticals. PepGen's average media sentiment score of 0.94 beat Actinium Pharmaceuticals' score of 0.00 indicating that PepGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ATNM or CNTB more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% Connect Biopharma N/A -122.29% -97.07%

Does the media prefer ATNM or CNTB?

In the previous week, Connect Biopharma had 3 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 4 mentions for Connect Biopharma and 1 mentions for Actinium Pharmaceuticals. Connect Biopharma's average media sentiment score of 0.89 beat Actinium Pharmaceuticals' score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ATNM or COYA?

In the previous week, Coya Therapeutics had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for Coya Therapeutics and 1 mentions for Actinium Pharmaceuticals. Coya Therapeutics' average media sentiment score of 0.94 beat Actinium Pharmaceuticals' score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Actinium Pharmaceuticals (ATNM) Competitors

$0.99 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$0.97 -0.02 (-1.72%)

As of 07:56 PM Eastern

Compare

ATNM vs. CUE, SPRO, PEPG, CNTB, and COYA

Should you buy Actinium Pharmaceuticals stock or one of its competitors? MarketBeat compares Actinium Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Actinium Pharmaceuticals include Cue Biopharma (CUE), Spero Therapeutics (SPRO), PepGen (PEPG), Connect Biopharma (CNTB), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical products" industry.

How does Actinium Pharmaceuticals compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

Actinium Pharmaceuticals has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Cue Biopharma's return on equity of -98.30% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Cue Biopharma has a beta of 2.51, indicating that its stock price is 151% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

Cue Biopharma has higher revenue and earnings than Actinium Pharmaceuticals. Cue Biopharma is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	4.65	-$26.60M	-$5.58	N/A
Actinium Pharmaceuticals	$90K	345.13	-$48.82M	-$0.75	N/A

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Actinium Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 405.05%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Cue Biopharma and Cue Biopharma both had 1 articles in the media. Cue Biopharma's average media sentiment score of 1.89 beat Actinium Pharmaceuticals' score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Cue Biopharma	Very Positive
Actinium Pharmaceuticals	Neutral

Summary

Actinium Pharmaceuticals beats Cue Biopharma on 8 of the 15 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Spero Therapeutics?

Actinium Pharmaceuticals (NYSE:ATNM) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Actinium Pharmaceuticals currently has a consensus price target of $5.00, indicating a potential upside of 405.05%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Spero Therapeutics has higher revenue and earnings than Actinium Pharmaceuticals. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	345.13	-$48.82M	-$0.75	N/A
Spero Therapeutics	$66.80M	1.96	$8.57M	$0.24	9.42

Actinium Pharmaceuticals has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

Spero Therapeutics has a net margin of 24.90% compared to Actinium Pharmaceuticals' net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Spero Therapeutics	24.90%	35.58%	24.95%

In the previous week, Actinium Pharmaceuticals and Actinium Pharmaceuticals both had 1 articles in the media. Spero Therapeutics' average media sentiment score of 1.87 beat Actinium Pharmaceuticals' score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
Spero Therapeutics	Very Positive

Summary

Spero Therapeutics beats Actinium Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to PepGen?

Actinium Pharmaceuticals (NYSE:ATNM) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

PepGen's return on equity of -59.89% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
PepGen	N/A	-59.89%	-49.62%

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Comparatively, 1.3% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Actinium Pharmaceuticals has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, PepGen has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market.

Actinium Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 405.05%. PepGen has a consensus price target of $11.50, indicating a potential upside of 546.07%. Given PepGen's higher possible upside, analysts clearly believe PepGen is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Actinium Pharmaceuticals has higher revenue and earnings than PepGen. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	345.13	-$48.82M	-$0.75	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

In the previous week, PepGen had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for PepGen and 1 mentions for Actinium Pharmaceuticals. PepGen's average media sentiment score of 0.94 beat Actinium Pharmaceuticals' score of 0.00 indicating that PepGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PepGen beats Actinium Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Connect Biopharma?

Actinium Pharmaceuticals (NYSE:ATNM) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Actinium Pharmaceuticals has higher revenue and earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	345.13	-$48.82M	-$0.75	N/A
Connect Biopharma	$60K	2,497.41	-$55.48M	-$1.15	N/A

Actinium Pharmaceuticals has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.22, suggesting that its stock price is 122% less volatile than the broader market.

In the previous week, Connect Biopharma had 3 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 4 mentions for Connect Biopharma and 1 mentions for Actinium Pharmaceuticals. Connect Biopharma's average media sentiment score of 0.89 beat Actinium Pharmaceuticals' score of 0.00 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Connect Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

27.5% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 0.6% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Actinium Pharmaceuticals currently has a consensus target price of $5.00, indicating a potential upside of 405.05%. Connect Biopharma has a consensus target price of $7.17, indicating a potential upside of 201.12%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Actinium Pharmaceuticals' return on equity of -100.85% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Connect Biopharma	N/A	-122.29%	-97.07%

Summary

Actinium Pharmaceuticals beats Connect Biopharma on 9 of the 16 factors compared between the two stocks.

How does Actinium Pharmaceuticals compare to Coya Therapeutics?

Actinium Pharmaceuticals (NYSE:ATNM) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Coya Therapeutics has higher revenue and earnings than Actinium Pharmaceuticals. Coya Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$90K	345.13	-$48.82M	-$0.75	N/A
Coya Therapeutics	$7.95M	17.91	-$21.23M	-$1.15	N/A

In the previous week, Coya Therapeutics had 1 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for Coya Therapeutics and 1 mentions for Actinium Pharmaceuticals. Coya Therapeutics' average media sentiment score of 0.94 beat Actinium Pharmaceuticals' score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Actinium Pharmaceuticals currently has a consensus target price of $5.00, suggesting a potential upside of 405.05%. Coya Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 152.61%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Actinium Pharmaceuticals is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Actinium Pharmaceuticals has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Actinium Pharmaceuticals has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

Summary

Coya Therapeutics beats Actinium Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Actinium Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATNM vs. The Competition

Export

Metric	Actinium Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$31.06M	$1.00B	$6.85B	$23.32B
Dividend Yield	N/A	4.84%	2.66%	4.07%
P/E Ratio	-0.71	1.00	22.00	28.65
Price / Sales	345.13	119.91	550.72	21.10
Price / Cash	N/A	20.06	29.09	18.60
Price / Book	0.76	8.06	10.98	4.78
Net Income	-$48.82M	-$3.83M	$3.57B	$1.07B
7 Day Performance	-3.88%	2.31%	3.06%	1.42%
1 Month Performance	-21.43%	0.42%	0.72%	0.76%
1 Year Performance	-30.28%	53.34%	36.82%	25.45%

Actinium Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATNM Actinium Pharmaceuticals	2.1508 of 5 stars	$0.99 flat	$5.00 +405.1%	-30.3%	$31.06M	$90K	N/A	30
CUE Cue Biopharma	0.5534 of 5 stars	$27.35 -11.0%	N/A	-96.2%	$129.08M	$27.47M	N/A	60	Positive News Gap Up
SPRO Spero Therapeutics	1.7539 of 5 stars	$2.15 -2.7%	N/A	-23.1%	$127.96M	$66.80M	8.96	150	Gap Down
PEPG PepGen	3.138 of 5 stars	$1.82 -0.5%	$11.50 +531.9%	+47.8%	$126.58M	N/A	N/A	30
CNTB Connect Biopharma	4.4861 of 5 stars	$2.09 +5.0%	$7.20 +244.5%	+120.5%	$125.30M	$233K	N/A	110	News Coverage Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ATNM) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. CUE, SPRO, PEPG, CNTB, and COYA

How does Actinium Pharmaceuticals compare to Cue Biopharma?

Summary

How does Actinium Pharmaceuticals compare to Spero Therapeutics?

Summary

How does Actinium Pharmaceuticals compare to PepGen?

Summary

How does Actinium Pharmaceuticals compare to Connect Biopharma?

Summary

How does Actinium Pharmaceuticals compare to Coya Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actinium Pharmaceuticals (ATNM) Competitors

ATNM vs. CUE, SPRO, PEPG, CNTB, and COYA

How does Actinium Pharmaceuticals compare to Cue Biopharma?

Is CUE or ATNM more profitable?

Which has more risk and volatility, CUE or ATNM?

Which has preferable earnings and valuation, CUE or ATNM?

Do insiders and institutionals hold more shares of CUE or ATNM?

Do analysts prefer CUE or ATNM?

Does the media refer more to CUE or ATNM?

Summary

How does Actinium Pharmaceuticals compare to Spero Therapeutics?

Do insiders & institutionals hold more shares of ATNM or SPRO?

Do analysts rate ATNM or SPRO?

Which has better earnings and valuation, ATNM or SPRO?

Which has more volatility & risk, ATNM or SPRO?

Is ATNM or SPRO more profitable?

Does the media prefer ATNM or SPRO?

Summary

How does Actinium Pharmaceuticals compare to PepGen?

Is ATNM or PEPG more profitable?

Do institutionals and insiders hold more shares of ATNM or PEPG?

Which has more risk and volatility, ATNM or PEPG?

Do analysts recommend ATNM or PEPG?

Which has higher valuation and earnings, ATNM or PEPG?

Does the media favor ATNM or PEPG?

Summary

How does Actinium Pharmaceuticals compare to Connect Biopharma?

Which has better valuation & earnings, ATNM or CNTB?

Which has more risk and volatility, ATNM or CNTB?

Does the media prefer ATNM or CNTB?

Do insiders and institutionals have more ownership in ATNM or CNTB?

Do analysts prefer ATNM or CNTB?

Is ATNM or CNTB more profitable?

Summary

How does Actinium Pharmaceuticals compare to Coya Therapeutics?

Which has higher earnings & valuation, ATNM or COYA?

Does the media favor ATNM or COYA?

Do institutionals and insiders hold more shares of ATNM or COYA?

Do analysts prefer ATNM or COYA?

Which has more risk & volatility, ATNM or COYA?

Is ATNM or COYA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM vs. The Competition

Actinium Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools